Hyperkalemia Is an Underestimated Risk Factor in COPD.

Area of Science:

• Pulmonology
• Nephrology
• Cardiology

Background:

• Hyperkalemia is a known mortality risk factor in general patient populations.
• The association between hyperkalemia and Chronic Obstructive Pulmonary Disease (COPD) is under-recognized.
• Hyperkalemia may contribute to cardiovascular mortality during and after COPD exacerbations.

Purpose of the Study:

• To investigate the prevalence and risk factors of hyperkalemia in patients with moderate-to-very severe COPD.
• To explore the relationship between hyperkalemia and comorbidities like chronic kidney disease (CKD), diabetes mellitus (DM), and renin-angiotensin-aldosterone system (RAAS) inhibitor use in COPD patients.

Main Methods:

• Retrospective analysis of a cohort of 7968 patients from two clinical trials with moderate-to-very severe COPD.
• Assessment of associations between hyperkalemia and comorbidities including CKD, DM, and RAAS inhibitor use.

Main Results:

• 6.4% of COPD patients experienced hyperkalemia, with increased prevalence in Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages 3 (6.8%) and 4 (8.0%) compared to GOLD 2 (5.3%).
• Hyperkalemia risk significantly increased with decreasing renal function (OR=2.29 for moderate-to-severe impairment) and was associated with DM (OR=1.28) and Angiotensin-Converting-Enzyme inhibitor (ACEi) use (OR=1.25).
• RAAS inhibitor use showed a significant association with hyperkalemia only in patients with normal renal function (OR=1.63).

Conclusions:

• Severe and very severe COPD patients (GOLD 3 and 4) face a higher risk of hyperkalemia.
• Decreasing kidney function, DM, and ACEi use are significant risk factors for hyperkalemia in COPD.
• Regular serum potassium monitoring is recommended for COPD patients, particularly those with GOLD stages 3 and 4.